mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide–PMO Conjugates
Bioconjugate Chemistry · 2023
DOI: 10.1021/acs.bioconjchem.3c00408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2023. Verfasst von Anna-Lina Lessl und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany. Hauptthemen laut MEDLINE: Dystrophin, Muscular Dystrophy, Duchenne. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for NanoScience, Ludwig-Maximilians-Universit?t M?nchen, Deutsche Forschungsgemeinschaft, Galenus Foundation.
Abstract (Originalsprache)
Phosphorodiamidate morpholino oligomers (PMOs) are a special type of antisense oligonucleotides (ASOs) that can be used as therapeutic modulators of pre-mRNA splicing. Application of nucleic-acid-based therapeutics generally requires suitable delivery systems to enable efficient transport to intended tissues and intracellular targets. To identify potent formulations of PMOs, we established a new in vitro-in vivo screening platform based on mdx exon 23 skipping. Here, a new in vitro positive read-out system (mCherry-DMDEx23) is presented that is sensitive toward the PMO(Ex23) sequence mediating DMD exon 23 skipping and, in this model, functional mCherry expression. After establishment of the reporter system in HeLa cells, a set of amphiphilic, ionizable xenopeptides (XPs) was screened in order to identify potent carriers for PMO delivery. The identified best-performing PMO formulation with high splice-switching activity at nanomolar concentrations in vitro was then translated to in vivo trials, where exon 23 skipping in different organs of healthy BALB/c mice was confirmed. The predesigned in vitro-in vivo workflow enables evaluation of PMO(Ex23) carriers without change of the PMO sequence and formulation composition. Furthermore, the identified PMO-XP conjugate formulation was found to induce highly potent exon skipping in vitro and redistributed PMO activity in different organs in vivo.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Biotechnology, Department of Pharmacy, LMU Munich, Butenandtstrasse 5-13, 81377 Munich, Germany.
- Center for NanoScience (CeNS), LMU Munich, 80799 Munich, Germany.
- Department of Pharmaceutical Sciences, University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.
ORCID-Profile: Yi Lin, Ernst Wagner, Ulrich Lächelt
Förderung
- Center for NanoScience, Ludwig-Maximilians-Universit?t M?nchen
- Deutsche Forschungsgemeinschaft
- Galenus Foundation
Zitieren
APA
Lessl, A. L., Pöhmerer, J., Lin, Y., Wilk, U., Höhn, M., Hörterer, E., Wagner, E., & Lächelt, U. (2023). mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide–PMO Conjugates. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.3c00408
Vancouver
Lessl AL, Pöhmerer J, Lin Y, Wilk U, Höhn M, Hörterer E, et al. mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide–PMO Conjugates. Bioconjugate Chemistry. 2023. doi:10.1021/acs.bioconjchem.3c00408
BibTeX
@article{Lessl2023,
author = {Lessl, Anna-Lina and Pöhmerer, Jana and Lin, Yi and Wilk, Ulrich and Höhn, Miriam and Hörterer, Elisa and Wagner, Ernst and Lächelt, Ulrich},
title = {mCherry on Top: A Positive Read-Out Cellular Platform for Screening DMD Exon Skipping Xenopeptide–PMO Conjugates},
journal = {Bioconjugate Chemistry},
year = {2023},
doi = {10.1021/acs.bioconjchem.3c00408}
}
EUVIMED